TIDMMTFB

RNS Number : 2921E

Motif Bio PLC

05 May 2017

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

Motif Bio plc

("Motif Bio" or the "Company")

Motif Bio Announces Appointment of Dr. Craig Albanese as Non-Executive Director

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the appointment of Dr. Craig T. Albanese to the Company's Board as Non-Executive Director with immediate effect.

Dr. Albanese has 25 years of clinical and administrative experience focusing on children and women's health, primarily in the Stanford Children's Hospital, New-York Presbyterian Hospital, Morgan Stanley Children's Hospital and the Sloane Hospital for Women. He has had a distinguished clinical career to date having published 161 peer review articles, contributed 57 book chapters, and risen to Professor of Surgery in Paediatrics, Obstetrics and Gynecology. He has combined his clinical career with success in hospital administrative positions where he has had a pivotal role in setting up networks of physicians, support, and educational services across a number of hospitals and medical institutions to provide integrated clinical and support services for increasing numbers of patients in a very cost-effective way.

Richard Morgan, Chairman of Motif Bio, commented: "I am delighted to welcome Craig to the Board of Motif Bio. We have seen great progress in the development of iclaprim, our lead antibiotic for serious Gram-positive infections, and with the publication of the successful completion of the first Phase III clinical trial, the Board is now increasingly focused on the commercialisation of iclaprim in the US. Craig's experience and knowledge of both the clinical reality and operational activities of large hospital groups will prove invaluable in refining our commercialisation strategy for iclaprim. We look forward to his input to the team."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

   -      Full name and age: Craig Thomas Albanese (aged 55)

Dr. Albanese has been granted options to acquire 100,000 ordinary shares of 1p each in the Company at a price of 33.75p. The options granted have a vesting period of 48 months, may be exercised up to the tenth anniversary of the grant and are not subject to performance criteria.

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information please contact:

 
 Motif Bio plc                          info@motifbio.com 
  Richard Morgan (Chairman) 
  Graham Lumsden (Chief 
  Executive Officer) 
 Peel Hunt LLP (NOMAD 
  & BROKER) 
  Dr. Christopher Golden/ 
  Oliver Jackson                      +44 (0)20 7418 8900 
 Northland Capital Partners 
  Limited (BROKER) 
  Patrick Claridge/ David 
  Hignell 
  John Howes/ Rob Rees 
  (Broking)                           +44 (0)20 3861 6625 
 Walbrook PR Ltd. (FINANCIAL       +44 (0)20 7933 8780 or 
  PR & IR)                        motifbio@walbrookpr.com 
  Paul McManus                   Mob: +44 (0)7980 541 893 
  Mike Wort                      Mob: +44 (0)7900 608 002 
 
 MC Services AG (EUROPEAN 
  IR) 
 Raimund Gabriel                       +49 (0)89 210 2280

About Motif Bio plc www.motifbio.com

Notes to Editors:

Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected in the second half of 2017.

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

 
 1.   Details of the person discharging managerial 
       responsibilities / person closely associated 
---  --------------------------------------------------------------------- 
 a.   Name                            Craig Thomas Albanese 
---  ------------------------------  ------------------------------------- 
 2.   Reason for the notification 
---  --------------------------------------------------------------------- 
 a.   Position/status                 Non-Executive Director 
---  ------------------------------  ------------------------------------- 
 b.   Initial notification            Initial 
       /Amendment 
---  ------------------------------  ------------------------------------- 
 3.   Details of the issuer, emission allowance 
       market participant, auction platform, auctioneer 
       or auction monitor 
---  --------------------------------------------------------------------- 
 a.   Name                            Motif Bio plc 
---  ------------------------------  ------------------------------------- 
 b.   LEI                             54930080DN00QTIUUU84 
---  ------------------------------  ------------------------------------- 
 4.   Details of the transaction(s): section to 
       be repeated for (i) each type of instrument; 
       (ii) each type of transaction; (iii) each 
       date; and (iv) each place where transactions 
       have been conducted 
---  --------------------------------------------------------------------- 
 a.   Description                     Grant of options over ordinary 
       of the                          shares of 1p each in Motif Bio 
       Financial                       plc 
       instrument, 
       type 
       of instrument 
       Identification 
       code 
---  ------------------------------  ------------------------------------- 
 b.   Nature of 
       the transaction                  Grant of options to acquire shares 
---  ------------------------------  ------------------------------------- 
 c.   Price(s)                          Price(s)   Volume(s) 
       and volume(s)                    ---------  ---------- 
                                         33.75p     100,000 
                                        ---------  ---------- 
---  ------------------------------  ------------------------------------- 
 d.        Aggregated 
            information 
             *    Aggregated volume                N/A 
 
 
             *    Price 
---  ------------------------------  ------------------------------------- 
 e.   Date of the                     2017-05-05; 
       transaction 
---  ------------------------------  ------------------------------------- 
 f.   Place of                        Outside a trading venue 
       the transaction 
---  ------------------------------  -------------------------------------

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUVOVRBVAVRRR

(END) Dow Jones Newswires

May 05, 2017 02:01 ET (06:01 GMT)

Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Motif Bio Charts.
Motif Bio (LSE:MTFB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Motif Bio Charts.